Integra LifeSciences (IART) reports Q3 2026 results on October 21, with trader-implied odds of 75.5% favoring an earnings beat driven by the company's October 2 preliminary results. Flooding at its Cincinnati facility disrupted production, leading management to narrow Q3 revenue guidance to $410–412 million and adjusted EPS to $0.55–$0.59 while cutting full-year 2026 targets to $1.634–1.654 billion in revenue and $2.30–2.40 in EPS. These ranges encompass consensus estimates near $0.56 EPS and $412–426 million in revenue, supported by the prior quarter's 24% EPS beat. The stock trades near $13.21 amid analyst target revisions lower, reflecting tempered expectations ahead of the actual print and any fourth-quarter framing.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado1H6H1D7D30DALL
View resolved

Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes